Pharming Group N.V. (PHGUF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -10.54 Million USD | -177.14% |
| 2022 | 13.67 Million USD | -14.52% |
| 2021 | 15.99 Million EUR | -57.62% |
| 2020 | 37.74 Million EUR | -6.93% |
| 2019 | 40.55 Million EUR | 41.86% |
| 2018 | 28.58 Million EUR | 131.25% |
| 2017 | -91.47 Million EUR | -395.99% |
| 2016 | -18.44 Million EUR | -69.42% |
| 2015 | -10.88 Million EUR | -55.23% |
| 2014 | -7.01 Million EUR | 66.28% |
| 2013 | -20.79 Million EUR | 34.73% |
| 2012 | -31.86 Million EUR | -43.73% |
| 2011 | -22.16 Million EUR | 66.81% |
| 2010 | -66.78 Million EUR | 0.0% |
| 2009 | - USD | 100.0% |
| 2008 | -36.47 Million EUR | -15.62% |
| 2007 | -31.55 Million EUR | 0.0% |
| 2006 | - USD | 100.0% |
| 2005 | -21.15 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -1.04 Million USD | 13.4% |
| 2024 Q2 | -1.19 Million USD | 90.35% |
| 2024 Q1 | -12.37 Million USD | -346.58% |
| 2023 FY | -10.54 Million USD | -177.14% |
| 2023 Q4 | -2.77 Million USD | -180.0% |
| 2023 Q1 | -12.2 Million USD | 16.56% |
| 2023 Q2 | 1.31 Million USD | 110.8% |
| 2023 Q3 | 3.46 Million USD | 162.62% |
| 2022 Q1 | 3.46 Million USD | 37.9% |
| 2022 Q2 | 15.74 Million USD | 354.84% |
| 2022 Q3 | 9.1 Million USD | -42.19% |
| 2022 Q4 | -14.63 Million USD | -260.75% |
| 2022 FY | 13.67 Million USD | -14.52% |
| 2021 Q3 | -411.62 Thousand EUR | -106.98% |
| 2021 Q2 | 5.89 Million EUR | -30.84% |
| 2021 Q1 | 8.52 Million EUR | -19.45% |
| 2021 Q4 | 2.5 Million EUR | 709.73% |
| 2021 FY | 15.99 Million EUR | -57.62% |
| 2020 FY | 37.74 Million EUR | -6.93% |
| 2020 Q4 | 10.58 Million EUR | 9.68% |
| 2020 Q1 | 9.29 Million EUR | -34.66% |
| 2020 Q2 | 11.11 Million EUR | 19.54% |
| 2020 Q3 | 9.64 Million EUR | -13.18% |
| 2019 Q2 | 7.88 Million EUR | 4.24% |
| 2019 FY | 40.55 Million EUR | 41.86% |
| 2019 Q4 | 14.22 Million EUR | 30.94% |
| 2019 Q3 | 10.86 Million EUR | 37.71% |
| 2019 Q1 | 7.56 Million EUR | -49.47% |
| 2018 Q4 | 14.97 Million EUR | 138.99% |
| 2018 Q2 | 3.24 Million EUR | -52.05% |
| 2018 FY | 28.58 Million EUR | 131.25% |
| 2018 Q3 | 6.26 Million EUR | 93.06% |
| 2018 Q1 | 6.76 Million EUR | 113.11% |
| 2017 Q2 | -28.42 Million EUR | -362.77% |
| 2017 Q1 | -6.14 Million EUR | 8.75% |
| 2017 Q3 | -9.7 Million EUR | 65.84% |
| 2017 FY | -91.47 Million EUR | -395.99% |
| 2017 Q4 | -51.64 Million EUR | -431.97% |
| 2016 Q1 | -3.83 Million EUR | 9.7% |
| 2016 FY | -18.44 Million EUR | -69.42% |
| 2016 Q4 | -6.73 Million EUR | -59.48% |
| 2016 Q3 | -4.22 Million EUR | -15.51% |
| 2016 Q2 | -3.65 Million EUR | 4.75% |
| 2015 Q1 | -1.43 Million EUR | -108.49% |
| 2015 FY | -10.88 Million EUR | -55.23% |
| 2015 Q4 | -4.24 Million EUR | -55.82% |
| 2015 Q3 | -2.72 Million EUR | -10.26% |
| 2015 Q2 | -2.47 Million EUR | -71.96% |
| 2014 Q3 | 3.53 Million EUR | 165.11% |
| 2014 Q4 | 16.93 Million EUR | 379.13% |
| 2014 FY | -7.01 Million EUR | 66.28% |
| 2014 Q1 | -22.05 Million EUR | -278.62% |
| 2014 Q2 | -5.42 Million EUR | 75.39% |
| 2013 Q3 | -5.58 Million EUR | -129.96% |
| 2013 Q4 | -5.82 Million EUR | -4.26% |
| 2013 FY | -20.79 Million EUR | 34.73% |
| 2013 Q1 | -6.95 Million EUR | -754.06% |
| 2013 Q2 | -2.42 Million EUR | 65.08% |
| 2012 Q2 | -12.31 Million EUR | -42.36% |
| 2012 Q3 | -10.08 Million EUR | 18.13% |
| 2012 FY | -31.86 Million EUR | -43.73% |
| 2012 Q4 | -814.49 Thousand EUR | 91.92% |
| 2012 Q1 | -8.65 Million EUR | -113.52% |
| 2011 Q2 | -6.45 Million EUR | -30.6% |
| 2011 Q1 | -4.94 Million EUR | 75.04% |
| 2011 Q3 | -6.71 Million EUR | -3.98% |
| 2011 Q4 | -4.05 Million EUR | 39.66% |
| 2011 FY | -22.16 Million EUR | 66.81% |
| 2010 Q4 | -19.81 Million EUR | -124.47% |
| 2010 Q3 | -8.82 Million EUR | 62.86% |
| 2010 Q2 | -23.76 Million EUR | 0.0% |
| 2010 FY | -66.78 Million EUR | 0.0% |
| 2010 Q1 | - USD | 100.0% |
| 2009 FY | - USD | 100.0% |
| 2009 Q4 | -12.09 Million EUR | -3.1% |
| 2009 Q3 | -11.73 Million EUR | 9.33% |
| 2009 Q1 | -8.24 Million EUR | 0.0% |
| 2009 Q2 | -12.93 Million EUR | -56.94% |
| 2008 FY | -36.47 Million EUR | -15.62% |
| 2007 FY | -31.55 Million EUR | 0.0% |
| 2006 FY | - USD | 100.0% |
| 2005 FY | -21.15 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -689.857% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -51.056% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 119.91% |
| Nascent Biotech, Inc. | -2.08 Million USD | -405.249% |
| Rebus Holdings, Inc. | -1.02 Million USD | -934.118% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 116.195% |
| Qrons Inc. | -789.34 Thousand USD | -1236.294% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1567.913% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 83.15% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -2438.756% |
| Skye Bioscience, Inc. | -37.64 Million USD | 71.98% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 85.929% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -60.399% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -3758.055% |
| SQZ Biotechnologies Company | -79.46 Million USD | 86.726% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -264.681% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -479.392% |
| Mesoblast Limited | -87.95 Million USD | 88.008% |
| Marizyme, Inc. | -65.34 Million USD | 83.858% |
| Genus plc | 7.9 Million USD | 233.519% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 3.156% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -386.125% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -184.295% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -19.267% |
| ContraFect Corporation | -65.15 Million USD | 83.81% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -115.879% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -510.609% |
| IMV Inc. | -36.48 Million USD | 71.09% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -30.874% |
| MultiCell Technologies, Inc. | -380.07 USD | -2775178.238% |
| ONE Bio Corp. | 8.67 Million USD | 221.568% |
| Accustem Sciences Inc. | -3.74 Million USD | -181.549% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 79.595% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -732.43% |
| Q BioMed Inc. | -2.05 Million USD | -414.012% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -182.561% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -343.031% |
| Biomind Labs Inc. | -1.21 Million USD | -768.635% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 82.339% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -240.064% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -33.467% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -441.131% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -70332.692% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 33.541% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -81.323% |
| GB Sciences, Inc. | -1.36 Million USD | -674.633% |
| Alpha Cognition Inc. | -13.77 Million USD | 23.413% |
| HST Global, Inc. | -146.21 Thousand USD | -7114.281% |
| CSL Limited | 2.64 Billion USD | 100.399% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -501.104% |
| Halberd Corporation | -79.67 Thousand USD | -13138.616% |
| Enzolytics Inc. | -2.17 Million USD | -384.557% |
| Agentix Corp. | -1.37 Million USD | -667.568% |
| Resverlogix Corp. | -3.61 Million USD | -192.188% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -232.594% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 96.425% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 10863.265% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 252.327% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -165.493% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -248.563% |
| AVAX Technologies, Inc. | -6.41 Million USD | -64.462% |
| Zenith Capital Corp. | -10.59 Million USD | 0.453% |
| Genscript Biotech Corporation | -95.47 Million USD | 88.952% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -45283.358% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -154.418% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -17351.842% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -426.055% |
| Kadimastem Ltd | -3.3 Million USD | -218.921% |
| Helix BioMedix, Inc. | -1.05 Million USD | -898.81% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -176.198% |
| BioStem Technologies, Inc. | -8.48 Million USD | -24.343% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -2289.837% |
| LadRx Corporation | 400.44 Thousand USD | 2734.083% |
| Cell Source, Inc. | -5.32 Million USD | -98.226% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1130.573% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1130.573% |
| NovAccess Global Inc. | -4.76 Million USD | -121.17% |
| Affymax, Inc. | -14.42 Million USD | 26.872% |
| Itoco Inc. | -1.86 Million USD | -464.367% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -137.432% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -531.995% |
| Mobile Lads Corp. | -2.26 Million USD | -366.047% |
| CytoDyn Inc. | -49.84 Million USD | 78.837% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -13246.324% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -4523.74% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -1020.305% |
| SYBLEU INC | -180.3 Thousand USD | -5750.12% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -554.043% |
| International Stem Cell Corporation | -131 Thousand USD | -7951.908% |
| Bioxytran, Inc. | -4.28 Million USD | -146.448% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -19335.436% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -316.876% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 78.058% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -398.959% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -1250.772% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -232.955% |
| Neutra Corp. | -233.46 Thousand USD | -4418.022% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 48.016% |
| PureTech Health plc | -65.69 Million USD | 83.944% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 50.401% |
| IXICO plc | -1.17 Million USD | -795.416% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -6.256% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 81.536% |
| CSL Limited | 2.64 Billion USD | 100.399% |
| Cellectis S.A. | -103.17 Million USD | 89.776% |